New drug claims to boost female sex drive for 7 hours



The advantage of Vyleesi is it can be used as needed.

Vyleesi™ (bremelanotide injection) is a melanocortin receptor agonist developed by Palatin indicated for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD). The women didn't report having more sex, the original goal for the drug. "The problem is they are distressed about sex", Dr Krop from AMAG explained about women with low sex urges.

Now referred to as Vyleesi, the medicine is said to cause side effects that include: headaches, nausea, discomfort on injection site and increased blood pressure. It also could interfere with oral naltrexone, a drug for people with alcohol and opioid dependence, the FDA said.

According to the agency, HSDD is not caused by any medical or psychiatric condition, relationship issues or drug side effects.

Black bear nestles down for nap in closet after entering Montana home
Montana Fish, Wildlife and Parks showed up to assist and tranquillize the bear so he could be relocated. Once trapped inside, the bear reportedly damaged the mudroom before "he decided he was exhausted ".

"There are women who, for no known reason, have reduced sexual desire that causes marked distress, and who can benefit from safe and effective pharmacologic treatment", said Dr. Hylton Joffe, who directs the FDA's Center for Drug Evaluation and Research's Division of Bone, Reproductive and Urologic Products.

The pharmaceutical industry has pointed to surveys in recent years that indicate the sexual disorder is the most common among females across the nation, affecting one in 10 women. Amag estimates almost 6 million USA women meet the criteria for the drug. Those companies and others studied and later abandoned drugs acting on blood flow, testosterone and other targets.

Amag plans to market Vyleesi through social media and a website,, that tells women having a low sex drive "is nothing to blush about".

This is the second sex drug designed for ladies after the inception of Addyi which was released to the markets in 2015. The first, Addyi, went on sale in 20165 but needs users to take a pill every day. Around 20 percent of women dropped out early, Bloomberg reported. Women balked at the $800 monthly costs a year ago, which was lowered to $400. It was prescribed just 6,000 times a year ago, according to investment analyst data. The approval was based on women's responses to questionnaires that showed increases in sexual desires and decreases related to stress. Instead, she recommends counseling to help women "separate all the stresses of life" from their sex life.

Recommended News

We are pleased to provide this opportunity to share information, experiences and observations about what's in the news.
Some of the comments may be reprinted elsewhere in the site or in the newspaper.
Thank you for taking the time to offer your thoughts.